benign prostatic hyperplasia benign prostatic hyperplasia
Conditions
Interventions
crossovertrial
Sponsors
Ukimura Osamu
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1) male patients (50 years or older, male patient younger than 90 years,and prostate volume is 20 mL or more In the sonography,and IPSS score 8 or more, and QOL score 3 or more) 2) the patients who acquired an agreement for participation of this study
Exclusion criteria
Exclusion criteria: 1) the patients with prostate cancer 2) the patients with neurogenic bladder 3) the patients who was treated with other alpha1blockers or drug for overactive bladder 4) the patients who Tadalafil is administration contraindication 5) the patient who was judged to be inappropriateby by a doctor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The amount of change of the international prostate symptom score (IPSS) in each drug dosage start 12 weeks later | — |
Secondary
| Measure | Time frame |
|---|---|
| The amount of change of the following item each drug dosage start 12 weeks later QOL, IPSS-vas, overactivity bladder symptom score (OABSS), OABSS-vas, individual score of IPSS, NIH- Chronic Prostatitis Symptom Index (NIH-CPSI), a satisfaction questionnaire, adverse event and side effect | — |
Contacts
Public ContactAtuko Iwata
University Hospital Kyoto Prefectural University of Medicine
Outcome results
None listed